Search

Speech

Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).

Raghav, Kanwal Pratap Singh Yoshino, Takayuki Guimbaud, Rosine Chau, Ian Van den Eynde, Marc[UCL] Maurel, Joan Tie, Jeanne Kim, Tae Won Yeh, Kun-Huei Barrios, Daniel Kobayashi, Kojiro Bako, Emarjola Aregay, Mehreteab Meinhardt, Gerold Siena, Salvatore (2021) 2021 ASCO Annual Meeting I —

Speech

Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).

Raghav, Kanwal Pratap Singh Yoshino, Takayuki Guimbaud, Rosine Chau, Ian Van den Eynde, Marc[UCL] Maurel, Joan Tie, Jeanne Kim, Tae Won Yeh, Kun-Huei Barrios, Daniel Kobayashi, Kojiro Bako, Emarjola Aregay, Mehreteab Meinhardt, Gerold Siena, Salvatore (2022) 2022 ASCO Gastrointestinal Cancers Symposium —

Journal article

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Tabernero, Josep Yoshino, Takayuki Cohn, Allen Lee Obermannova, Radka Bodoky, Gyorgy Garcia-Carbonero, Rocio Ciuleanu, Tudor-Eliade Portnoy, David C Van Cutsem, Eric Grothey, Axel Prausová, Jana Garcia-Alfonso, Pilar Yamazaki, Kentaro Clingan, Philip R Lonardi, Sara Kim, Tae Won Simms, Lorinda Chang, Shao-Chun Nasroulah, Federico RAISE Study Investigators Van den Eynde, Marc[UCL] Humblet, Yves[UCL] (2015) The Lancet Oncology — Vol. 16, p. 499-508 (2015)

Journal article

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: A retrospective, exploratory analysis of the CORRECT trial

Tabernero, Josep Lenz, Heinz-Josef Siena, Salvatore Sobrero, Alberto Falcone, Alfredo Ychou, Marc Humblet, Yves[UCL] Bouché, Olivier Mineur, Laurent Barone, Carlo Adenis, Antoine Yoshino, Takayuki Goldberg, Richard M. Sargent, Daniel J. Wagner, Andrea Laurent, Dirk Teufel, Michael Jeffers, Michael Grothey, Axel Van Cutsem, Eric (2015) The Lancet Oncology — Vol. 16, no. 8, p. 937-948 (2015)

Journal article

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

André, Thierry Shiu, Kai-Keen Kim, Tae Won Jensen, Benny Vittrup Jensen, Lars Henrik Punt, Cornelis Smith, Denis Garcia-Carbonero, Rocio Benavides, Manuel Gibbs, Peter de la Fouchardiere, Christelle Rivera, Fernando Elez, Elena Bendell, Johanna Le, Dung T Yoshino, Takayuki Van Cutsem, Eric Yang, Ping Farooqui, Mohammed Z H Marinello, Patricia Diaz, Luis A KEYNOTE-177 Investigators Van den Eynde, Marc[UCL] (2020) The New England journal of medicine — Vol. 383, no.23, p. 2207-2218 (2020)

Journal article

Combined BRAF, EGFR, and MEK Inhibition in Patients with -Mutant Colorectal Cancer.

Corcoran, Ryan B André, Thierry Atreya, Chloe E Schellens, Jan H M Yoshino, Takayuki Bendell, Johanna C Hollebecque, Antoine McRee, Autumn J Siena, Salvatore Middleton, Gary Muro, Kei Gordon, Michael S Tabernero, Josep Yaeger, Rona O'Dwyer, Peter J Humblet, Yves[UCL] De Vos, Filip Jung, A Scott Brase, Jan C Jaeger, Savina Bettinger, Severine Mookerjee, Bijoyesh Rangwala, Fatima Van Cutsem, Eric (2018) Cancer discovery — Vol. 8, no.4, p. 428-443 (2018)

Journal article

Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study.

Mlecnik, Bernhard Torigoe, Toshihiko Bindea, Gabriela Popivanova, Boryana Xu, Mingli Fujita, Tomonobu Hazama, Shoichi Suzuki, Nobuaki Nagano, Hiroaki Okuno, Kiyotaka Hirohashi, Yoshihiko Furuhata, Tomohisa Takemasa, Ichiro Patel, Prabhudas Vora, Hemangini Shah, Birva Patel, Jayendrakumar B Rajvik, Kruti N Pandya, Shashank J Shukla, Shilin N Wang, Yili Zhang, Guanjun Yoshino, Takayuki Taniguchi, Hiroya Bifulco, Carlo Lugli, Alessandro Lee, Jiun-Kae Jack Zlobec, Inti Rau, Tilman T Berger, Martin D Nagtegaal, Iris D Vink-Börger, Elisa Hartmann, Arndt Geppert, Carol I Kolwelter, Julie Merkel, Susanne Grützmann, Robert Van den Eynde, Marc[UCL] Mourin, Anne[UCL] Kartheuser, Alex[UCL] Léonard, Daniel[UCL] Remue, Christophe[UCL] Wang, Julia Bavi, Prashant Roehrl, Michael H A Ohashi, Pamela S Nguyen, Linh T Han, SeongJun MacGregor, Heather L Hafezi-Bakhtiari, Sara Wouters, Bradly G Masucci, Giuseppe V Andersson, Emilia Zavadova, Eva Vocka, Michal Spacek, Jan Petruzelka, Lubos Konopasek, Bohuslav Dundr, Pavel Skalova, Helena Nemejcova, Kristyna Botti, Gerardo Tatangelo, Fabiana Delrio, Paolo Ciliberto, Gennaro Maio, Michele Laghi, Luigi Grizzi, Fabio Marliot, Florence Fredriksen, Tessa Buttard, Bénédicte Lafontaine, Lucie Maby, Pauline Majdi, Amine Hijazi, Assia El Sissy, Carine Kirilovsky, Amos Berger, Anne Lagorce, Christine Paustian, Christopher Ballesteros-Merino, Carmen Dijkstra, Jeroen Van de Water, Carlijn van Lent-van Vliet, Shannon Knijn, Nikki Mușină, Ana-Maria Scripcariu, Dragos-Viorel Marincola, Francesco M Ascierto, Paolo A Fox, Bernard A Pagès, Franck Kawakami, Yutaka Galon, Jérôme (2022) Cancers — Vol. 14, no. 18, p. 4346 [1-19] (2022)

Speech

Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.

Raghav, Kanwal Pratap Singh Siena, Salvatore Takashima, Atsuo Kato, Takeshi Van den Eynde, Marc[UCL] Di Bartolomeo, Maria Komatsu, Yoshito Kawakami, Hisato Peeters, Marc Andre, Thierry Lonardi, Sara Yamaguchi, Kensei Tie, Jeanne Gravalos Castro, Cristina Strickler, John H Barrios, Daniel Yan, Qi Kamio, Takahiro Kobayashi, Kojiro Yoshino, Takayuki (2023) American Society of ClinicalOncology (ASCO)2023 — McCormick Place, 2301 S King Dr, Chicago, IL 60616, USA

Journal article

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.

Dasari, Arvind Lonardi, Sara Garcia-Carbonero, Rocio Elez, Elena Yoshino, Takayuki Sobrero, Alberto Yao, James García-Alfonso, Pilar Kocsis, Judit Cubillo Gracian, Antonio Sartore-Bianchi, Andrea Satoh, Taroh Randrian, Violaine Tomasek, Jiri Chong, Geoff Paulson, Andrew Scott Masuishi, Toshiki Jones, Jeremy Csőszi, Tibor Cremolini, Chiara Ghiringhelli, Francois Shergill, Ardaman Hochster, Howard S Krauss, John Bassam, Ali Ducreux, Michel Elme, Anneli Faugeras, Laurence[UCL] Kasper, Stefan Van Cutsem, Eric Arnold, Dirk Nanda, Shivani Yang, Zhao Schelman, William R Kania, Marek Tabernero, Josep Eng, Cathy FRESCO-2 Study Investigators (2023) Lancet — Vol. 401, no. 10395, p. 41-53 (2023)

Journal article

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Grothey, Axel Van Cutsem, Eric Sobrero, Alberto Siena, Salvatore Falcone, Alfredo Ychou, Marc Humblet, Yves[UCL] Bouché, Olivier Mineur, Laurent Barone, Carlo Adenis, Antoine Tabernero, Josep Yoshino, Takayuki Lenz, Heinz-Josef Goldberg, Richard M Sargent, Daniel J Cihon, Frank Cupit, Lisa Wagner, Andrea Laurent, Dirk CORRECT Study Group (2013) The Lancet — Vol. 381, no.9863, p. 303-12 (2013)

Journal article

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: An international consortium study

Geva, Ravit Vecchione, Loredana Kalogeras, Konstantinos T. Jensen, Benny Vittrup Lenz, Heinz-Josef Yoshino, Takayuki Paez, David Montagut, Clara Souglakos, John Cappuzzo, Federico Cervantes, Andrés Frattini, Milo Fountzilas, George Johansen, Julia S. Høgdall, Estrid Vilma Zhang, Wu Yang, Dongyun Yamazaki, Kentaro Nishina, Tomohiro Papamichael, Demetris Vincenzi, Bruno Macarulla, Teresa Loupakis, Fotios De Schutter, Jef Spindler, Karen Lise Garm Pfeiffer, Per Ciardiello, Fortunato Piessevaux, Hubert[UCL] Tejpar, Sabine (2015) Gut — Vol. 64, no. 6, p. 921-928 (2015)

Journal article

Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.

Raghav, Kanwal Siena, Salvatore Takashima, Atsuo Kato, Takeshi Van den Eynde, Marc[UCL] Pietrantonio, Filippo Komatsu, Yoshito Kawakami, Hisato Peeters, Marc Andre, Thierry Lonardi, Sara Yamaguchi, Kensei Tie, Jeanne Castro, Cristina Gravalos Hsu, Hung-Chih Strickler, John H Kim, Tae-You Cha, Yongjun Barrios, Daniel Yan, Qi Kamio, Takahiro Kobayashi, Kojiro Boran, Aislyn Koga, Makito Allard, John D Yoshino, Takayuki (2024) The Lancet. Oncology — Vol. 25, no.9, p. 1147-1162 (2024)

User menu

Author

Date

Document Type

Access

Footer Help

Languages

Footer menu